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CD34 CELLS PURIFIED AUTOLOGOUS PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION FOR THE TREATMENT OF REFRACTORY AU-
TOIMMUNE DISEASES
Nagafuji, K., Miyamoto, T., Fukuda, T., Tsukamoto, H., Horiuchi, T.,
Harada, M. First Department of Internal Medicine, Kyushu University
Hospital, Fukuoa, Japan.
The aim of this study was to evaluate the safety and efﬁcacy of
CD34 cells in autologous peripheral blood stem cell transplan-
tation (PBSCT) for the treatment of refractory autoimmune dis-
eases (AD). Methods: Six cases of systemic sclerosis (SSc) with
interstitial pneumonia (IP), one case of amyopathic dermatomyo-
sitis (ADM) with IP, and one case of Wegener’s granulomatosis
with exophthalmous. PBSCs were mobilized with CY 4 g/m2 
G-CSF, and CD34 cells were puriﬁed with CliniMACS. Pre-
transplantation conditioning consisted of CY 200 mg/kg. Result:
There was no treatment-related mortality. Hematologic recoveries
after PBSCT of six patients with SSc were neutrophils  500 on
days 9–11 and platelets  5  104 days 10–20. Improvements in
skin scores and PaO2 were observed. The patient with ADM/IP
enjoyed dramatic improvement of her IP lasting more than 18
months. Five of eight patients became positive for cytomegalovirus
antigenemia, which was successfully treated with gancyclovir or
foscarnet. Two of eight patients developed adenoviral hemorrhagic
cystitis, which was successfully treated with cidofovir.Conclusion:
This treatment could be done with acceptable toxicity, resulting in
signiﬁcant improvement of AD.
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RECOVERY FROM AND CONSEQUENCES OF SEVERE IATROGENIC LYM-
PHOPENIA (INDUCED TO TREAT AUTOIMMUNE DISEASES)
Storek, J., Zhao, Z., McSweeney, P.A., Nash, R.A., Akatsuka, Y.,
Sullivan, K.M., Maloney, D.G. Fred Hutchinson Cancer Research Cen-
ter and University of Washington, Seattle, WA.
To ascertain the consequences of severe leukopenia and the
tempo of recovery, we studied the immunity of 56 adult patients
treated for multiple sclerosis or systemic sclerosis with autologous
CD34 cell transplantation using extremely lymphoablative condi-
tioning. Results: NK cell, monocyte, and neutrophil counts re-
covered to normal by 1 month, dendritic cell and B cell counts by
6 months and T cell counts by 2 years posttransplantation, al-
though CD4 T cell counts remained borderline low. Initial pe-
ripheral expansion was robust for CD8 T cells but only moderate
for CD4 T cells. Subsequent thymopoiesis was slow, especially in
older patients. Importantly, levels of antibodies, including autoan-
tibodies, did not drop substantially. Infections were frequent dur-
ing the ﬁrst 6 months, when all immune cells were deﬁcient, and
surprisingly rare (0.21 per patient year) at 7–24 months posttrans-
plantation, when only T cells (particularly CD4 T cells) were
deﬁcient. Conclusion: Peripheral expansion of CD8 but not CD4
T cells is highly efﬁcient. Prolonged CD4 lymphopenia is associ-
ated with relatively few infections, possibly due to antibodies pro-
duced by persisting pretransplantation plasma cells. The clinical
relevance of the persistence of autoantibodies needs to be studied.
192
TREATMENT OF POSTTRANSPLANTATION DIABETES MELLITUS WITH
ANTI-CD20 MONOCLONAL ANTIBODIES
Vandenbosch, K., Champagne, M.A., Gonthier, M., Moghrabi, A.,
Vachon, M.-F., Duval, M. Sainte-Justine Hospital, Montreal, Quebec,
Canada.
Anti-CD20 has been successfully used for the treatment of im-
mune manifestations after HSCT. We report the use of this treat-
ment for post-HSCT diabetes mellitus. An 11-year-old boy re-
ceived a HSCT from an HLA-identical sibling for AML CR1.
Preparative regimen consisted of fractioned TBI and etoposide,
along with graft-versus-host prophylaxis of cyclosporin and meth-
otrexate. SCT resulted in full donor engraftment. Cyclosporin was
discontinued on day 28 posttransplantation due to renal failure.
Subsequently, acute grade III skin GVHD was successfully treated
with glucocorticoids, with no glucose intolerance. Glucocorticoids
were discontinued at 5 months posttransplantation. At that time,
buccal lichen planus was present. No speciﬁc treatment was given.
At 12 months posttransplantation, the patient developed bronchi-
olitis obliterans and vitiligo (face, arms, and hips). Prednisone (up
to 1 mg/kg/day) was resumed; pulmonary function improved, but
skin lesions persisted unchanged. Again, glucocorticoid therapy did
not induce glucose intolerance. At 22 months posttransplantation,
glucocorticoids were tapered and azathioprine and hydroxychloro-
quine begun. Mofetylmycofenolate was substituted for azathio-
prine at 28 months posttransplantation. At 31 months posttrans-
plantation, the patient discontinued all treatment, including
glucocorticoids. His condition remained stable thereafter until he
developed hypothyroidism at 69 months posttransplantation,
treated with L-thyroxine. Antimicrosomal and antithyroglobulin
antibodies were negative. At 81 months posstransplantation, the
patient experienced polyuria, polydipsia, and major weight loss.
Hos blood sugar level was 36 mmol/l (648 mg/dl). He had keto-
nuria but no ketoacidosis. His HbA1c level was 13.4% (normal,
4.8% to 6.0%). The diagnosis of diabetes mellitus was made.
Diabetes was controlled with insulin, 1.1 U/kg/day. Tests for
associated autoantibodies were all negative, including anti–glu-
tamic acid decarboxylase (GAD) antibodies. There was no history
of diabetes mellitus in the donor or in the more extended family.
The patient’s body mass index was in the 72nd percentile. Four
doses of weekly intravenous (IV) rituximab(375 mg/m2/dose) were
administered, followed by monthly IV gammaglobulins. Insulin
was discontinued 3 months after the last dose of rituximab therapy.
Four months later, the patient remains free of symptoms and
normoglycemic, with an HbA1c level of 6,1%. Although the pa-
tient may be experiencing a “honeymoon” phenomenon with spon-
taneous, transitory remission of diabetes, our experience could also
suggest that diabetes mellitus developing after SCT may be of
immune origin, and that early treatment with anti-CD20 might
modify the course of the disease.
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INTENSIVE IMMUNOSUPPRESSION AND TRANSPLANTATION OF T-CELL
DEPLETED AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PA-
TIENTS WITH SYSTEMIC SCLEROSIS: AN ONGOING PHASE I TRIAL
BuchBarker, D.1, Donnenberg, A.D.1, Medsger, T.A.2, Carroll, M.P.1,
Grifﬁn, D.L.1, Blair, C.2, Lis, D.1, Yeager, A.M.1 1University of
Pittsburgh Cancer Institute, Pittsburgh, PA; 2Division of Rheumatology,
Department of Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, PA.
In patients who undergo autologous peripheral blood stem cell
transplantation (PBSCT) for severe autoimmune disorders, a pre-
parative regimen that optimizes immunosuppression without ex-
cessive myelotoxicity would potentially have favorable safety and
efﬁcacy proﬁles. We are conducting a phase I trial of cyclophos-
phamide (CY) dose escalation (initial dose 200 mg/m2/day  5,
days 7 to 3) plus ﬂudarabine (25 mg/m2/day  5, days 7 to
3) and rabbit anti-thymocyte globulin (ATG) (thymoglobulin;
2.5 mg/kg/day  3, days 5 to 3) followed by T-cell–depleted
(TCD) autologous PBSCT in adults with systemic sclerosis (SSc).
To date, 5 patients (median age, 44 years; range, 39–59 years) have
been treated on this study. Each patient had satisfactory PBSC
collection with one 4-hour large-volume leukapheresis after mo-
bilization with CY (2000 mg/m2) plus G-CSF. To deplete T cells
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in the PBSC product, we used a combination of CD34 selection
and ex vivo incubation with anti-CD3 antibody, which resulted in
a mean 5.2-log reduction of T cells (range, 4.7–6.3 log). The ﬁnal
PBSC products contained a mean of 9.94 (range, 4.8–13.0)  106
CD34 cells/kg and 1.34 (range, 0.06–4.54)  103 CD3 cells/
kg. The daily dose of CY was 200 mg/m2 in the ﬁrst 3 patients and
400 mg/m2 in the next 2 patients. The mean half-life (t1/2) of
CD3 cells in these patients was biphasic: 0.8 days from day7 to
day5 and 0.2 days from day5 to day3, correlating with ATG
administration. In contrast, the mean t1/2 of CD3 cells was 2.5
days in patients with hematologic malignancies receiving a myeloa-
blative preparative regimen of CY, busulfan, and etoposide. After
PBSCT, the median nadirs of WBC, ANC, and platelets were 1.2
(range, 0.4–2.0), 0.9 (range, 0.1–1.7) and 135 (range, 114–185) 
109/L, respectively. All patients are alive at a median of 8.5
months (range, 6.9 to 17.5 months) after PBSCT. Compared
with pre-PBSCT levels, Rodnan total skin score (TSS) decreased
by 4, 10, 11, and 15 points, respectively, in 4 patients and increased
by 8 points in 1 patient, who also developed SSc renal crisis
requiring hemodialysis at 12 months after PBSCT. Of 4 patients
with improved TSS, 1 has worsening polymyositis and 1 has
recurrence of palpable tendon friction rubs. Even at the lowest CY
dose, this immunosuppressive regimen provides signiﬁcantly
greater and more rapid T-cell kill than a conventional myeloabla-
tive regimen. The efﬁcacy of this regimen and TCD PBSCT in
SSc is encouraging. but requires longer follow-up and experience
with a larger number of patients.
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CONSOLIDATION AND MOBILIZATION OF PERIPHERAL BLOOD STEM
CELLS USING HIGH-DOSE CYTARABINE AND ETOPOSIDE IN ACUTE
MYELOID LEUKEMIA: A SINGLE INSTITUTIONAL EXPERIENCE
Shu, F., Bashey, A., Carrier, E., Castro, J., Holman, P., Lane, T.,
Medina, B., Corringham, S., Ball, E.D. Division of Blood and Marrow
Transplantation, Department of Medicine, and Moores’ UCSD Cancer
Center, University of California at San Diego, La Jolla, CA.
Autologous hematopoietic stem cell transplantation (autoHSCT)
as consolidation in ﬁrst complete remission (CR1) is an option for
patients with AML. Achieving adequate numbers of stem cells and
eradicating residual leukemia cells with acceptable toxicity repre-
sent two conﬂicting goals. Between May 2000 and May 2004, we
performed autoHSCT in 24 AML patients using a reduced dose
modiﬁcation of a cytarabine/etoposide regimen reported by Linker
(BBMT 6:50–57, 2000) as a consolidation and stem cell mobiliza-
tion regimen. Median age at the time of HSCT was 59 (range,
21–73; 50%  60 years). Most patients had intermediate-risk
(63%) or high-risk cytogenetics (25%). All patients but 1 were in
CR1 before autoHSCT. After induction chemotherapy, 12 pa-
tients proceeded to consolidation/mobilization. Twleve patients
had additional consolidation with cytarabine-based regimens (8
with 1 consolidation and 4 with 2 consolidations). All patients then
received etoposide (5 mg/kg IV every 12 hours) and cytarabine (2
g/m2 IV every 12 hours) for 3 days instead of the 4 days described
by Linker. Patients received G-CSF (10 g/kg SC) on day 14 until
the WBC count was 10,000. The median number of CD34
stem cells collected was 5.9  106/kg (range, 1.3–75.5). Some 92%
of patients received busulfan and cyclophosphamide as a condi-
tioning regimen. There were no treatment-related deaths. En-
graftment was rapid: WBC 1000 in 11.5 days (range, 9–19 days),
ANC 500 in 12 days (range, 10–21 days), and platelets 50,000
in 17 days (range, 11–214 days). Median follow-up is 13.6 months
(range, 2–52 months). Eleven patients (46%) relapsed at a median
of 5.4 months (range 1.2–27.5 months). Median disease-free sur-
vival (DFS) for all patients is 27.5 months. Patients with interme-
diate- and high-risk cytogenetics had a 1-year DFS of 54% and
50%, respectively. Patients receiving at least 1 consolidation before
the mobilization regimen had 1-year DFS and overall survival (OS)
of 56% and 73%, respectively compared with 46% and 64% for
those proceeding directly from induction to mobilization. Our data
suggest that autoHSCT using reduced doses of cytarabine and
etoposide as a consolidation and mobilization regimen is safe and
effective at achieving engraftment, and is associated with encour-
aging outcomes in patients with intermediate- to high-risk cyto-
genetics. At least 1 consolidation before the mobilization/consoli-
dation regimen may be associated with superior outcome.
Prospective trials with larger numbers of patients are needed to
validate our preliminary ﬁndings.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIGH-RISK
PEDIATRIC SOLID TUMORS
Fraser, C.J.1, Weigel, B.J.1, John, P.P.2, Todd, D.E.1, Kevin, B.S.1,
Michael, V.R.1 1University of Minnesota, Minneapolis, MN; 2Cincin-
nati Children’s Hospital Medical Center, Cincinnati, OH.
Aim: The purpose of this study was to determine the toxicity of
treatment with high-dose alkylating agents followed by ASCT, to
monitor treatment response and to promote disease free survival in
a group of pediatric patients with high risk solid tumors.Methods:
A total of 36 patients with solid tumors having disseminated disease
at diagnosis or following relapse were treated on 2 consecutive
autologous transplantation protocols at the University of Minne-
sota between May 1995 and March 2004. Preliminary data on 11 of
these patients have already been reported. The age range of the
patients was 2–26 years. Of the 36 patients, 20 had a diagnosis of
a Ewing’s family tumor (16 Ewing’s sarcoma and 4 desmoplastic
small round cell tumor). Other diagnoses included rhabdomyosar-
coma (in 3 patients), Wilm’s tumor (in 2), medulloblastoma (in 2),
and ependymoma, atypical teratoid rhabdoid tumor, glioblastoma
multiforme, osteosarcoma, hepatoblastoma, retinoblastoma, cervi-
cal chordoma, ovarian small cell carcinoma and ovarian mixed
anaplastic germ cell tumor each in 1 patient. Patients were eligible
for transplantation if they had a complete response (CR) (18
patients) or a very good partial response with nonprogressive
disease (18 patients). Conditioning therapy consisted of either oral
busulfan (12 mg/kg) or intravenous busulfan (9.6 mg/kg  4 years;
12 mg/kg  4 years), melphalan (100 mg/m2) and thiotepa (500
mg/m2). Thirteen patients received the chemoprotectant amifos-
tine. All patients received G-CSF until neutrophil engraftment.
Twenty patients received PBSC, 15 patients received autologous
bone marrow, and 1 patient received syngeneic marrow. Results:
Median time to neutrophil engraftment, deﬁned as the ﬁrst of 3
consecutive days of an ANC  0.5  109/L, was 11 days (range,
9–56 days). Overall survival was 63% (range, 47%-79%) at 1 year
and 33% (range, 16%-50%) at 3 years. Disease-free survival was
28% (range, 13%-43%) at 3 years. Median follow-up among sur-
vivors is 3.5 years (range, 0.6–7.9 years). Three-year overall sur-
vival for Ewing’s family tumors was signiﬁcantly better than for all
other diagnoses (54% vs 13%; P .03). Three-year overall survival
was signiﬁcantly better for those patients transplanted after CR
(48% vs 12%; P  .03). There were 2 toxic deaths attributed to
veno-occlusive disease. Conclusions: Our data indicate that
ASCT after high-dose alkylating agent therapy has acceptable
toxicity and should be considered as consolidation therapy for
patients with high-risk Ewing’s family tumors. The effectiveness of
this therapy for other diagnoses appears to be limited.
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TANDEM AUTOGRAFTS FOR MULTIPLE MYELOMA PATIENTS USING
TWO DIFFERENT CONDITIONING REGIMENS: AN INTERIM ANALYSIS
Liu, H.1, Roberts, C.2, Pumphrey, P.2, Wingard, J.R.1, Moreb, J.S.1
1University of Florida College of Medicine, Gainesville, FL; 2Shands
Hospital at University of Florida, Gainesville, FL.
Autologous stem cell transplantation (ASCT) has become a stan-
dard therapy for multiple myeloma (MM) patients. In the current
study, we evaluated the toxicity and efﬁcacy of tandem autografts
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